Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy-Reference-Cited by-同舟云学术

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

Published:2018-11-02 Issue:21 Volume:3 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Knaus Hanna A.,Berglund Sofia^ORCID,Hackl Hubert^ORCID,Blackford Amanda L.^ORCID,Zeidner Joshua F.,Montiel-Esparza Raúl,Mukhopadhyay Rupkatha,Vanura Katrina^ORCID,Blazar Bruce R.,Karp Judith E.,Luznik Leo,Gojo Ivana

Funder

Leukemia and Lymphoma Society

National Institutes of Health

American Society for Blood and Marrow Transplantation (ASBMT)

Vienna Fund for Innovative Cancer Research

Swedish Society for Medical Research

Wenner-Gren Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/120974/files/pdf

Reference82 articles.

1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2. Acute myeloid leukemia: 2016 Update on risk-stratification and management

3. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

4. Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

5. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Participation of T cells in generating immune protection against cancers;Pathology - Research and Practice;2024-10

2. PD-L1 and PD-1 in immune regulation and their implications in blood cancers;Advances in Cancer Biology - Metastasis;2024-10

3. A CD8+ T cell related immune score predicts survival and refines the risk assessment in acute myeloid leukemia;Frontiers in Immunology;2024-09-12

4. CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia;Blood;2024-09-12

5. Immune‐dysregulation harnessing in myeloid neoplasms;Cancer Medicine;2024-09